These results indicate that NR4A1 antagonists target multiple growth promoting and pro-survival pathways in RCC cells and in tumors (xenograft) and represent a novel chemotherapy for treating RCC. This evidence concerns the gene NR4A1 and renal cell adenocarcinoma.